<DOC>
	<DOCNO>NCT02045056</DOCNO>
	<brief_summary>The purpose study assess safety efficacy gemfibrozil modulate microRNA-107 level prevention Alzheimer 's disease subject intact cognition mild cognitive impairment</brief_summary>
	<brief_title>Modulation Micro-RNA Pathways Gemfibrozil Predementia Alzheimer Disease</brief_title>
	<detailed_description>Double-blind , placebo control , parallel-design . 48 cognitively-intact subject , 24 subject early cognitive decline ( CDR 0.5 ) randomly assign treatment gemfibrozil ( 600 mg orally twice day ) placebo 52 week . Safety assessment include routine assessment adverse event , safety lab , brain magnetic resonance imaging .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Gemfibrozil</mesh_term>
	<criteria>Participants must meet follow inclusion criterion order participate study : 1 . Men woman age 6590 , inclusive . 2 . Stable medical condition three month prior screen visit , clinically significant abnormality hepatic , renal , hematologic function define follow : Platelets &gt; 100,000 , Serum creatinine ≤ 1.6 mg/dL , aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤ 1.5 upper limit normal , No clinically significant abnormality laboratory study ( CBC , chemistry panel ) 3 . Nondiabetic well control diabetes confirm fast serum glucose &lt; 126 mg/dL . 4 . Stable medication 4 week prior screen visit . 5 . Physically acceptable study confirm medical history , physical exam , neurological exam clinical test . Exceptions criterion may consider casebycase basis , discretion Project Director . 1 . Female participant pregnant childbearing potential . 2 . Unstable medical condition three month prior screen visit poorly control blood pressure , diabetes , breathe problems…etc . 3 . Clinically significant abnormality liver , kidney blood test 4 . Significant neurologic disease Alzheimer 's disease , Parkinson 's disease , stroke , brain tumor , multiple sclerosis seizure disorder . 5 . Major depression past 12 month ( DSMIV criterion ) , major mental illness schizophrenia , recent ( past 12 month ) alcohol substance abuse . 6 . History invasive cancer within past two year . 7 . Contraindications lumbar puncture ( bleed disorder , platelet count &lt; 100,000 , anticoagulant treatment , major structural abnormality sepsis area lumbosacral spine would make lumbar puncture technically difficult ) . 8 . Use investigational agent within 30 day prior screen . 9 . Contraindications MRI ( metallic implant , pacemaker , shrapnel , ect… ) 10 . Sensitivity , intolerance , allergy gemfibrozil previous reaction cholesterol lower medicine . 11 . Major surgery within eight week prior Baseline Visit . 12 . Blindness , deafness , language difficulty disability may prevent potential participant participate cooperate protocol . 13 . Physically unacceptable study confirm medical history , physical exam , neurological exam clinical test . Exceptions criterion may consider casebycase basis , discretion examine study physician . Excluded Medications : 1 . Experimental drug 2 . Repaglinide 3 . `` Statins '' include limited atorvastatin ( Lipitor ) , fluvastatin ( Lescol ) , lovastatin ( Mevacor ) , pravastatin ( Pravachol ) , rosuvastatin ( Crestor ) , simvastatin ( Zocor ) , combination medicine contain drug . 4 . Coumadin , warfarin , heparin , lovenox , Xarelto , apixaban anticoagulant . ( Antiplatelet therapy acceptable ) . NOTE : If drug discontinue 4 week screen , participant eligible study .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Alzheimer disease</keyword>
	<keyword>mild cognitive impairment</keyword>
	<keyword>normal cognition</keyword>
</DOC>